The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

You most likely have beta thalassemia minor (one normal gene and one that causes low beta-cell-chain production), which ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Dear Dr. Roach: I am Greek and have thalassemia minor. In general, my red blood cells are much smaller than typical ones, and ...

I am Greek and have thalassemia minor. In general, my red blood cells are much smaller than typical ones, and my iron content is significantly low. Every time ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...